Drug intelligence / Profile preview

hydroxychloroquine + leflunomide + sulfasalazine

Development stage: Preclinical
Lead developer: Sanofi
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of hydroxychloroquine, leflunomide, and sulfasalazine used primarily for the treatment of rheumatoid arthritis. This combination represents an alternative approach when methotrexate cannot be used or is not tolerated. Each component has a distinct mechanism of action: hydroxychloroquine affects lysosomal activity and inhibits antigen presentation; leflunomide inhibits pyrimidine synthesis by blocking dihydroorotate dehydrogenase; and sulfasalazine has anti-inflammatory and immunomodulatory effects.

Other names: Triple therapy (Leflunomide, Sulfasalazine, Hydroxychloroquine)Lef-Combo

Targets

DHODH (Dihydroorotate dehydrogenase (quinone), mitochondrial)

Beyond the preview

Go deeper on hydroxychloroquine + leflunomide + sulfasalazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hydroxychloroquine + leflunomide + sulfasalazine.

Explore the full profile